ReAlta Life Sciences Presents Data for Hypoxic Ischemic Encephalopathy at PAS Meeting 2025
By Karen Roman
ReAlta Life Sciences said it is presenting new data from its hypoxic ischemic encephalopathy (HIE) program at the Pediatric Academic Societies Annual Meeting, taking place in Honolulu, Hawaii, from April 24-28, 2025.
The findings confirm elevated inflammatory biomarkers in newborns with HIE and demonstrate a predictable way the body interacts with RLS-0071 (pegtarazimod), the company stated.
'These biomarker findings represent a significant advancement in our understanding of the inflammatory pathways driving HIE in humans,' said Kenji M. Cunnion, MD, MPH, ReAlta's Chief Medical Officer.
Contact:
Executives-Edge.com
Editor@executives-edge.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 days ago
- Yahoo
Nanox AI Bone Solution Receives CE Mark Certification
By Karen Roman Nano-X Imaging Ltd. (Nasdaq: NNOX) said its AI bone solution HealthOST has received CE mark certification which enables its commercialization across Europe. HealthOST examines CT scans to assess vertebral height loss and bone mineral density and helps identify disease risk, such as osteoporosis, before fractures occur, it stated. 'This CE mark for HealthOST represents a significant expansion of our AI capabilities in Europe,' said Erez Meltzer, Nanox CEO and acting Chairman. 'By integrating seamlessly into routine CT scans, HealthOST helps healthcare providers maximize their existing resources, while identifying patients who might otherwise fall through the cracks of traditional screening methods.' Contact: Exec Edge Editor@
Yahoo
6 days ago
- Yahoo
Healthcare Information Exchange Market Trends, Opportunities, and Forecast, 2020-2024 & 2025-2030: Government Initiatives Propel Growth, Competitive Landscape, The Rise of AI and IoT Innovations
Key opportunities in the Healthcare Information Exchange market include increased digitization of healthcare, technological advancements like AI and IoT for improved data security and real-time sharing, government support for standardization and privacy, cost-efficiency measures, and enhanced patient-centric care models. Healthcare Information Exchange Market Dublin, June 03, 2025 (GLOBE NEWSWIRE) -- The "Healthcare Information Exchange Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to Healthcare Information Exchange Market was valued at USD 1.45 Billion in 2024, and is expected to reach USD 2.48 Billion by 2030, rising at a CAGR of 9.36% The Global Healthcare Information Exchange (HIE) Market is experiencing significant growth and transformation, driven by the increasing digitization of healthcare systems, growing demand for efficient data sharing, and a focus on improving patient care and outcomes. This market overview provides insights into the key drivers, challenges, trends, and opportunities shaping the HIE landscape worldwide. Moreover, Government support for healthcare information technology to improve care quality is another key driver. For instance, in May 2023, Ontario launched a health information exchange (HIE) system called eHub to improve patient care. This system, enabled by Oracle, allows 21 hospitals to securely share patient data, making communication more efficient and reducing the administrative burden. This collaboration between healthcare providers and TransForm aims to enhance care coordination for Ontarians. Regional InsightsNorth America emerged as the dominant region in the global Healthcare Information Exchange market in 2022, holding the largest market share in terms of value. The presence of numerous healthcare providers, hospitals, and clinics drives the demand for HIE solutions to enhance patient care and streamline operations. Strong Regulatory Environment: The United States has robust data privacy regulations like HIPAA, which mandate secure and interoperable data exchange in regulatory framework has stimulated HIE adoption as healthcare organizations strive to achieve compliance. Technological Advancements: North America is a global hub for healthcare technology innovation. The region has witnessed significant investments in electronic health records (EHRs), telehealth, and interoperability solutions, fostering the growth of the HIE market. Large and Diverse Population: The North American region's large and diverse population demands efficient healthcare data exchange to ensure patient-centric care, care coordination, and public health several strategic activities in the region by key market players, such as the launch of new technology, collaborations, and partnerships. For instance, according to the news reported on March 2024, Orion Health group of companies inaugurated the "State Health Data Center of Excellence (SHDCoE)" in the U.S. The primary focus of this strategic launch was to engage in new collaborations and be an innovation hub to elevate regional Health Information Exchange (HIE) operations in the health information exchange market was identified as a lucrative region in this industry. The increasing awareness in the government about the importance of healthcare data, investments in data centers, strategic partnerships, and advanced technologies are attributable to the growth in Europe. For instance, as per the news the World Health Organization published in December 2023, WHO and the European Commission entered into a partnership to support healthcare services for about 1 billion people, strengthen health information systems, and boost health data governance and interoperability in the European Region. This project cost USD 13.0 million and was supported by the European government. Such initiatives propelled the market growth and are expected to function similarly in the coming Insights Setup InsightBased on Setup, the private HIE segment emerged as the dominant player in the global market for Healthcare Information Exchange in 2024. Private HIEs give healthcare organizations greater control over patient data, ensuring compliance with data privacy regulations like HIPAA in the United States or GDPR in Europe. This control instills trust among patients that their sensitive health information is handled with care and in accordance with legal requirements. Customization: Private HIEs allow healthcare entities to tailor the system to their specific needs and workflows. This customization ensures that the HIE aligns seamlessly with existing processes, optimizing efficiency and usability. Data Security: By maintaining a private HIE, organizations can implement their security measures and protocols. This level of control mitigates security risks and minimizes the potential for data breaches, which is especially critical in the healthcare sector. Patient Access: Private HIEs empower patients by providing them with secure access to their health records and information. This access fosters active engagement in their healthcare journey and encourages them to take ownership of their health. Transparency: Patients appreciate transparency in their care. Private HIEs allow patients to view their test results, treatment plans, and medical history, creating a transparent and trusting relationship between patients and healthcare providers. Telehealth Integration: Many private HIEs offer integrated telehealth capabilities, allowing patients to participate in virtual consultations and receive remote care. This convenience and accessibility enhance patient satisfaction. Application InsightBased Application, the web portal development segment emerged as the dominant player in the global market for Healthcare Information Exchange in 2024. Web portals provide a user-friendly interface that healthcare providers, patients, and other stakeholders find easy to navigate. This accessibility encourages adoption and active engagement. The dominance of web portals in the Global Healthcare Information Exchange Market is a result of their accessibility, user-friendliness, real-time data sharing, patient-centered approach, and robust data security. These applications empower healthcare providers and patients alike by offering seamless access to critical healthcare information and enabling efficient collaboration. Web portals prioritize data privacy and compliance with regulations, ensuring that patient data remains secure and protected. In a healthcare landscape that values patient engagement, timely information sharing, and data security, web portals have emerged as the preferred application for HIE. Universal Access: Web-based portals are accessible from any device with an internet connection, making them a versatile tool for healthcare data exchange. Users can access critical patient information on desktops, laptops, tablets, and smartphones. Patient Empowerment: Patients appreciate the simplicity and accessibility of web portals, as they can easily access their medical records, lab results, appointment schedules, and communicate with healthcare providers. This empowerment enhances patient engagement and satisfaction. End-User InsightsBased on End-User, healthcare providers segment emerged as the dominant player in the global market for Healthcare Information Exchange. Healthcare providers, including hospitals, clinics, and physician practices, are the primary users of patient data. They require access to comprehensive medical records, test results, and treatment history to make informed clinical decisions and provide optimal patient care. Timely Diagnoses and Treatment: Healthcare providers rely on HIE systems to access critical patient information quickly. Timely access to data enables faster diagnoses, treatment planning, and interventions, ultimately improving patient outcomes. Care Coordination: Healthcare providers often work in multidisciplinary teams to provide coordinated care to patients. HIE systems facilitate seamless data sharing and communication among these teams, leading to more effective care coordination. Streamlined Data Exchange: Healthcare providers heavily depend on efficient data sharing to avoid redundant tests, unnecessary procedures, and delays in care delivery. HIE systems streamline the exchange of patient data, reducing administrative overhead and improving workflow efficiency. Integration with EHR Systems: Electronic Health Record (EHR) systems are integral to healthcare providers' daily operations. HIE systems can seamlessly integrate with EHRs, ensuring that providers have immediate access to patient data within their familiar workflow. Improved Patient Engagement: HIE systems empower healthcare providers to engage patients more actively in their care. They can share medical records, test results, and treatment plans with patients through secure portals, fostering greater patient engagement and adherence to treatment regimens. These factors collectively contribute to the growth of this segment. Key Attributes: Report Attribute Details No. of Pages 182 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $1.45 Billion Forecasted Market Value (USD) by 2030 $2.48 Billion Compound Annual Growth Rate 9.3% Regions Covered Global Report Scope: Key Market Players Allscripts Healthcare Solutions Inc. Cerner Corporation Open Text Corporation Conifer Health Solutions Epic Corporation Inc. Infor, Inc Medicity, Inc. NextGen Healthcare Information Systems LLC Optum Inc. Orion Health Healthcare Information Exchange Market, By Implementation Model: Centralized /Consolidated Models Decentralized / Federated Models Hybrid Model Healthcare Information Exchange Market, By Setup Type: Private Public Healthcare Information Exchange Market, By Application: Internal Interfacing Secure Messaging Workflow Management Web portal Development Other Healthcare Information Exchange Market, By Exchange Type: Direct Exchange Query-based Exchange Consumer Mediated Exchange Healthcare Information Exchange Market, By Component: Enterprise Master Person Index (EMPI) Healthcare Provider Directory (HPD) Record Locator Service (RLS) Clinical Data Repository Other Healthcare Information Exchange Market, By End-User: Public Health Agencies Healthcare Providers Others Healthcare Information Exchange Market, By Region: North America United States Canada Mexico Europe France United Kingdom Italy Germany Spain Asia-Pacific China India Japan Australia South Korea South America Brazil Argentina Colombia Middle East & Africa South Africa Saudi Arabia UAE For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Healthcare Information Exchange Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
30-05-2025
- Medscape
Iron Over Dopamine? Restless Legs Syndrome Guidelines Revamp
To reduce the risk for complications, the use of dopaminergic agonists in the treatment of severe restless legs syndrome (RLS) has become less common. RLS is characterized by an irresistible urge to move the legs, often accompanied by unpleasant sensations such as itching, tingling, or electric paresthesia, which typically affect the lower limbs. It affects 8% of the French population, predominantly women. New guidelines from the American Academy of Sleep Medicine (AASM) no longer recommend the use of these drugs as first-line treatments. During the recent French Language Neurology Days in Montpellier, France, Sofiène Chenini, PhD, a researcher at the Sleep-Wake Disorders Unit, Department of Neurology, Gui-de-Chauliac Hospital, reviewed the current treatment approaches for RLS and highlighted non-dopaminergic alternatives. He cautioned that dopaminergic agonists could lead to the augmentation and worsening of symptoms over time. In France, RLS is guided by the 2019 recommendations of the French Society for Sleep Research and Medicine (SFRMS), which still supports the use of dopaminergic agonists for the most severe cases of RLS. 'For now, we have not updated the guidelines, but we are considering it,' said Chenini, referring to the new American recommendations. Iron as First Line According to the new AASM guidelines, intravenous iron supplementation is the preferred first-line treatment for severe RLS. In some cases, second-line antiepileptic drugs are considered a first-line treatment option in French recommendations when the severity is low. These sensations of restlessness typically occur in the evening or at night during periods of rest or inactivity and are temporarily relieved by movement, such as walking and stretching. The condition often leads to repeated leg movements during sleep and difficulty falling asleep due to increased brain activity. RLS is not fully understood but is often linked to problems with iron regulation. MRI studies have shown iron deficiency in the brains of patients with RLS. This suggests a disruption in iron transport across the blood-brain barrier and into neurons, possibly due to a decrease in the transferrin receptor. This disruption in iron regulation, believed to have a primarily genetic origin, induces an increase in the synthesis of dopamine and glutamate, which is likely the cause of the symptoms. In RLS, changes in the dopaminergic system are linked to risk factors such as aging and the use of certain medications. Five Clinical Criteria According to a 2016 consensus from the SFRMS, RLS diagnosis is based on five clinical criteria: An intense and irresistible urge to move the lower limbs accompanied by unpleasant sensations Worsening symptoms at rest, the patient is unable to stay still Relief of symptoms through movement such as walking or stretching Increased severity of symptoms in the evening and at night The absence of other causes, such as myalgia, fibromyalgia, osteoarthritis, venous insufficiency, and obliterative arteriopathy of the lower limbs Once diagnosed, iron assessment is required to check for iron deficiency. The analysis includes measuring C-reactive protein to ensure there is no inflammation, 'which reduces iron bioavailability,' Chenini explained. Therefore, polysomnography remains optional in such cases. If ferritin levels are below 75 µg/L, iron supplementation is recommended. Treatment also involves addressing factors that worsen symptoms, such as caffeine and alcohol consumption and smoking. It is advisable to stop or switch medications that may aggravate symptoms, such as antidepressants and antihistamines. The antidepressants involved are serotonergic, particularly serotonin reuptake inhibitors, with a long half-life. 'If stopping treatment is not possible, switching to antidepressants with a short half-life, such as venlafaxine or duloxetine taken in the morning, is recommended,' he said. Lifestyle For mild RLS cases, lifestyle changes may be sufficient to ease symptoms. These include avoiding coffee, alcohol, and tobacco; maintaining regular sleep and wake times; engaging in physical activity early in the day; and performing stretching exercises before sleeping. If ferritin levels remain low after 3 months of iron supplementation, switching to intravenous treatment is recommended. Options included a single dose of ferric carboxymaltose (500-1000 mg) or multiple sessions of 200 mg ferric hydroxide-sucrose. If symptoms persist, a mild opioid is recommended as needed, starting with opium powder, codeine (such as paracetamol-codeine 500/30 mg, up to 60 mg of codeine or more), and tramadol (starting at 50 mg and increasing to 100 mg if necessary). If the improvement remains insufficient, specific treatment should be considered on the basis of the severity of RLS assessed using the International Restless Legs Syndrome Severity Scale (IRLS) score. Background treatment is recommended for very severe cases (IRLS score above 30), which are linked to the risks for depression and even suicide, as noted by Chenini. It is also advised in cases of severe insomnia or when the quality of life is significantly affected. A recent study by Chenini and colleagues found a 10-fold higher risk for depressive symptoms in patients with RLS, particularly in young women with insomnia. The study also reported a threefold increase in suicidal thoughts. Dose and Misuse According to the French guidelines, very severe cases of RLS require treatment with low-dose dopamine agonists, such as pramipexole, rotigotine, or ropinirole. These drugs may also help reduce motor inhibition in patients with depression. Dopamine agonists are the only approved treatment for this indication. 'It is essential to respect the maximum dosages,' Chenini emphasized. The recommended maximum doses are 3 mg for rotigotine, 0.54 mg for pramipexole, and 4 mg for ropinirole. Second-line treatments include alpha-2 delta ligand antiepileptics, such as gabapentin and pregabalin, especially in cases of severe insomnia. For less severe cases, these antiepileptics are preferred as first-line treatment. Gabapentin may be favored over pregabalin because it causes less sedation. The major risk associated with dopamine agonists is worsening symptoms after prolonged use, known as augmentation syndrome, which is particularly higher in patients with iron deficiency, older age, and those prescribed high doses of antagonists. Concerns about this complication led the AASM to remove dopamine agonists from the recommendations for RLS management. In 2016, American guidelines similar to the current French recommendations for dopamine agonists were the first-line treatment alongside antiepileptics in the treatment of severe forms of the disease. The new recommendations now place intravenous iron supplementation as the first-line treatment, while antiepileptics are the second line. Chenini highlighted that this change is due to the misuse of dopamine agonists in RLS. A registry of 670,000 patients with RLS in the United States showed that 60% were treated with dopamine agonists, and 20% received doses exceeding the recommended limits. The registry shows that neurologists prescribe higher doses of dopamine agonists for RLS than general practitioners. This is likely because these drugs are also used to treat Parkinson's disease, where the doses are approximately 10 times higher than those used for RLS. Chenini reported having no conflicts of interest.
